| VP-0008 |
Aloxi® (palonosetron) (Intravenous) |
|
| VP-0014 |
Bevacizumab: Avastin®; Mvasi®; Zirabev™; Alymsys® (Intravenous) |
|
| VP-0043 |
Faslodex® (fulvestrant) (Intramuscular) |
|
| VP-0059 |
SCIG (immune globulin SQ): Hizentra®, Gammagard Liquid®, Gamunex®-C, Gammaked®, Hyqvia®, Cuvitru®, Cutaquig®, Xembify® (Subcutaneous) |
|
| VP-0071 |
Immune Globulins (immunoglobulin) (Intravenous) |
|
| VP-0072 |
Ixempra® (ixabepilone) (Intravenous) |
|
| VP-0089 |
Nplate™ (romiplostim) (Subcutaneous) |
|
| VP-0100 |
Provenge® (sipuleucel-T) (Intravenous) |
|
| VP-0137 |
Velcade® (bortezomib) (Intravenous/Subcutaneous) |
|
| VP-0161 |
Zaltrap® (ziv-aflibercept) (Intravenous) |
|
| VP-0200 |
Sylvant™ (siltuximab) (Intravenous) |
|
| VP-0208 |
Arzerra® (ofatumumab) (Intravenous) |
|
| VP-0225 |
Blincyto® (blinatumomab) (Intravenous) |
|
| VP-0235 |
Colony Stimulating Factors: Filgrastim (Neupogen®); Filgrastim-aafi (Nivestym™); Filgrastim-sndz (Zarxio®); Filgrastim-ayow (Releuko®); Tbo-Filgrastim (Granix®) (Subcutaneous/Intravenous) |
|
| VP-0237 |
Colony Stimulating Factors: Leukine® (sargramostim) (Subcutaneous/Intravenous) |
|
| VP-0243 |
Epoetin alfa: Epogen®; Procrit®; Retacrit® (Subcutaneous/Intravenous) |
|
| VP-0266 |
Darzalex™ (daratumumab) (Intravenous) |
|
| VP-0267 |
Portrazza™ (necitumumab) (Intravenous) |
|
| VP-0268 |
Empliciti™ (elotuzumab) (Intravenous) |
|
| VP-0274 |
Imlygic™ (talimogene laherparepvec) Intralesional |
|
| VP-0283 |
Sustol® (granisetron extended-release) (Subcutaneous) |
|
| VP-0317 |
Besponsa (inotuzumab ozogamicin) (Intravenous) |
|
| VP-0320 |
Mylotarg (gemtuzumab ozogamicin) (Intravenous) |
|
| VP-0322 |
Rituxan Hycela™ (rituximab and hyaluronidase human) (Subcutaneous) |
|
| VP-0333 |
Yescarta™ (axicabtagene ciloleucel) (Intravenous) |
|
| VP-0336 |
Cinvanti™ (aprepitant) (Intravenous) |
|
| VP-0351 |
Bortezomib* (Intravenous Only) |
|
| VP-0363 |
Akynzeo® (fosnetupitant/palonosetron) (Intravenous) |
|
| VP-0378 |
Poteligeo® (mogamulizumab-kpkc) (Intravenous) |
|
| VP-0393 |
Lumoxiti™ (moxetumomab pasudotox-tdfk) (Intravenous) |
|
| VP-0398 |
Libtayo® (cemiplimab-rwlc) (Intravenous) |
|
| VP-0426 |
Elzonris™ (tagraxofusp-erzs) (Intravenous) |
|
| VP-0449 |
Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) (Subcutaneous) |
|
| VP-0503 |
Reblozyl® (luspatercept-aamt) (Subcutaneous) |
|
| VP-0528 |
Sarclisa® (isatuximab-irfc) (Intravenous) |
|
| VP-0531 |
Jelmyto™ (mitomycin) (Intra-pyelocalyceal) |
|
| VP-0532 |
Trodelvy™ (sacituzumab govitecan-hziy) (Intravenous) |
|
| VP-0535 |
Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) (Subcutaneous) |
|
| VP-0550 |
Zepzelca™ (lurbinectedin) (Intravenous) |
|
| VP-0553 |
Phesgo™ (pertuzumab, trastuzumab and hyaluronidase-zzxf) (Subcutaneous) |
|
| VP-0558 |
Tecartus™ (brexucabtagene autoleucel) (Intravenous) |
|
| VP-0559 |
Monjuvi™ (tafasitamab-cxix) (Intravenous) |
|
| VP-0561 |
Blenrep® (belantamab mafodotin-blmf) (Intravenous) |
|
| VP-0581 |
Danyelza® (naxitamab-gqgk) (Intravenous) |
|
| VP-0583 |
Margenza™ (margetuximab-cmkb) (Intravenous) |
|
| VP-0590 |
Breyanzi® (lisocabtagene maraleucel) (Intravenous) |
|
| VP-0598 |
Abecma® (idecabtagene vicleucel) (Intravenous) |
|
| VP-0600 |
Zynlonta™ (loncastuximab tesirine-lpyl) (Intravenous) |
|
| VP-0607 |
Rybrevant™ (amivantamab-vmjw) (Intravenous) |
|
| VP-0624 |
Tivdak™ (tisotumab vedotin-tftv) (Intravenous) |
|
| VP-0647 |
Fyarro™ (sirolimus albumin-bound) (Intravenous) |
|
| VP-0658 |
Kimmtrak® (tebentafusp-tebn) (Intravenous) |
|
| VP-0663 |
Carvykti™ (ciltacabtagene autoleucel) (Intravenous) |
|
| VP-0664 |
Opdualag™ (nivolumab/relatlimab-rmbw) (Intravenous) |
|
| VP-90057 |
Trastuzumab: Herceptin®; Ogivri®; Kanjinti™; Trazimera™; Herzuma®; Ontruzant® (Intravenous) |
|
| VP-90109 |
Rituximab: Rituxan®, Truxima®, Ruxience®, Riabni™ (Intravenous) |
|
